Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (61)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Glatt, H.
Right arrow Articles by Phillips, D. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Glatt, H.
Right arrow Articles by Phillips, D. H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Carcinogenesis, Vol 19, 1709-1713, Copyright © 1998 by Oxford University Press

ARTICLES

Rat, but not human, sulfotransferase activates a tamoxifen metabolite to produce DNA adducts and gene mutations in bacteria and mammalian cells in culture

H Glatt, W Davis, W Meinl, H Hermersdorfer, S Venitt and DH Phillips
German Institute of Human Nutrition, Department of Toxicology, Potsdam- Rehbrucke.

Tamoxifen increases the risk of human endometrial cancer and is a potent carcinogen in rat liver, in which it produces DNA adducts and cytogenetic damage. Nevertheless its prophylactic use against breast cancer in healthy women is under investigation in several large trials. To investigate whether rat hepatocarcinogenicity predicts human hepatocarcinogenicity we used genetically engineered bacterial and mammalian target cells to investigate how alpha-hydroxy-tamoxifen, a major phase I metabolite of tamoxifen, is further metabolised by rat and human phase II enzymes, sulfotransferases, to mutagenic and DNA- adduct-forming species. We expressed rat hydroxysteroid sulfotransferase a, a liver-specific enzyme, and corresponding human sulfotransferase in bacteria (Salmonella typhimurium) and in a mammalian cell line (Chinese hamster V79 cells) and tested alpha- hydroxytamoxifen for DNA adduct formation and mutagenicity in these systems, using unmodified cells as controls. In cells that expressed rat hydroxysteroid sulfotransferase, alpha-hydroxytamoxifen was mutagenic and formed the same pattern of DNA adducts as that found in the liver of tamoxifen-treated rats. Alpha-hydroxytamoxifen was not activated, or was at least 20 times less active in cells expressing human hydroxysteroid sulfotransferase. All the other six known human xenobiotic-metabolising sulfotransferases were also expressed in S. typhimurium. None activated alpha-hydroxytamoxifen to a mutagen. These results suggest that the risk of DNA adduct formation, and cancer, in the human liver is low and explain why tamoxifen is a powerful carcinogen to the rat liver, and why standard short-term tests fail to detect its mutagenicity.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 MutagenesisHome page
K. Brown
Is tamoxifen a genotoxic carcinogen in women?
Mutagenesis, September 1, 2009; 24(5): 391 - 404.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
V. M. Arlt, H. Glatt, G. Gamboa da Costa, J. Reynisson, T. Takamura-Enya, and D. H. Phillips
Mutagenicity and DNA Adduct Formation by the Urban Air Pollutant 2-Nitrobenzanthrone
Toxicol. Sci., August 1, 2007; 98(2): 445 - 457.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Brown, E. M. Tompkins, D. J. Boocock, E. A. Martin, P. B. Farmer, K. W. Turteltaub, E. Ubick, D. Hemingway, E. Horner-Glister, and I. N.H. White
Tamoxifen Forms DNA Adducts in Human Colon after Administration of a Single [14C]-Labeled Therapeutic Dose
Cancer Res., July 15, 2007; 67(14): 6995 - 7002.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
S. Y. Kim, Y. R. S. Laxmi, N. Suzuki, K. Ogura, T. Watabe, M. W. Duffel, and S. Shibutani
FORMATION OF TAMOXIFEN-DNA ADDUCTS VIA O-SULFONATION, NOT O-ACETYLATION, OF {alpha}-HYDROXYTAMOXIFEN IN RAT AND HUMAN LIVERS
Drug Metab. Dispos., November 1, 2005; 33(11): 1673 - 1678.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
M. J. Zamek-Gliszczynski, K. A. Hoffmaster, X. Tian, R. Zhao, J. W. Polli, J. E. Humphreys, L. O. Webster, A. S. Bridges, J. C. Kalvass, and K. L. R. Brouwer
MULTIPLE MECHANISMS ARE INVOLVED IN THE BILIARY EXCRETION OF ACETAMINOPHEN SULFATE IN THE RAT: ROLE OF MRP2 AND BCRP1
Drug Metab. Dispos., August 1, 2005; 33(8): 1158 - 1165.
[Abstract] [Full Text] [PDF]

Home page
 MutagenesisHome page
D. H. Phillips, A. Hewer, M. R. Osborne, K. J. Cole, C. Churchill, and V. M. Arlt
Organ specificity of DNA adduct formation by tamoxifen and {alpha}-hydroxytamoxifen in the rat: implications for understanding the mechanism(s) of tamoxifen carcinogenicity and for human risk assessment
Mutagenesis, July 1, 2005; 20(4): 297 - 303.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
T. I. Apak and M. W. Duffel
INTERACTIONS OF THE STEREOISOMERS OF {alpha}-HYDROXYTAMOXIFEN WITH HUMAN HYDROXYSTEROID SULFOTRANSFERASE SULT2A1 AND RAT HYDROXYSTEROID SULFOTRANSFERASE STA
Drug Metab. Dispos., December 1, 2004; 32(12): 1501 - 1508.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
H. Glatt, U. Pabel, W. Meinl, H. Frederiksen, H. Frandsen, and E. Muckel
Bioactivation of the heterocyclic aromatic amine 2-amino-3-methyl-9H-pyrido [2,3-b]indole (MeA{alpha}C) in recombinant test systems expressing human xenobiotic-metabolizing enzymes
Carcinogenesis, May 1, 2004; 25(5): 801 - 807.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
S. Maiti and G. Chen
Tamoxifen Induction of Aryl Sulfotransferase and Hydroxysteroid Sulfotransferase in Male and Female Rat Liver and Intestine
Drug Metab. Dispos., May 1, 2003; 31(5): 637 - 644.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
W. Teubner, W. Meinl, and H. Glatt
Stable expression of rat sulfotransferase 1B1 in V79 cells: activation of benzylic alcohols to mutagens
Carcinogenesis, November 1, 2002; 23(11): 1877 - 1884.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
M. Yadollahi-Farsani, D. S. Davies, and A. R. Boobis
The mutational signature of {alpha}-hydroxytamoxifen at Hprt locus in Chinese hamster cells
Carcinogenesis, November 1, 2002; 23(11): 1947 - 1952.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
C. A. Strott
Sulfonation and Molecular Action
Endocr. Rev., October 1, 2002; 23(5): 703 - 732.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
T. Kasahara, M. Hashiba, T. Harada, and M. Degawa
Change in the gene expression of hepatic tamoxifen-metabolizing enzymes during the process of tamoxifen-induced hepatocarcinogenesis in female rats
Carcinogenesis, March 1, 2002; 23(3): 491 - 498.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
G. Gamboa da Costa, L.P. McDaniel-Hamilton, R. H. Heflich, M.M. Marques, and F. A. Beland
DNA adduct formation and mutant induction in Sprague-Dawley rats treated with tamoxifen and its derivatives
Carcinogenesis, August 1, 2001; 22(8): 1307 - 1315.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
D. H. Phillips
Understanding the genotoxicity of tamoxifen?
Carcinogenesis, June 1, 2001; 22(6): 839 - 849.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
D. J. Boocock, J. L. Maggs, K. Brown, I. N.H. White, and B.K. Park
Major inter-species differences in the rates of O-sulphonation and O-glucuronylation of {alpha}-hydroxytamoxifen in vitro: a metabolic disparity protecting human liver from the formation of tamoxifen-DNA adducts
Carcinogenesis, October 1, 2000; 21(10): 1851 - 1858.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
W. Davis, A. Hewer, K. M. Rajkowski, W. Meinl, H. Glatt, and D. H. Phillips
Sex Differences in the Activation of Tamoxifen to DNA Binding Species in Rat Liver in Vivo and in Rat Hepatocytes in Vitro: Role of Sulfotransferase Induction
Cancer Res., June 1, 2000; 60(11): 2887 - 2891.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
H. Bartsch, D. H. Phillips, J. Nair, A. Hewer, G. Meyberg-Solomeyer, and E.-M. Grischke
Lack of evidence for tamoxifen- and toremifene-DNA adducts in lymphocytes of treated patients
Carcinogenesis, April 1, 2000; 21(4): 845 - 847.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
D. H. Phillips, A. Hewer, M. N. Horton, K. J. Cole, P. L. Carmichael, W. Davis, and M. R. Osborne
N-Demethylation accompanies {alpha}-hydroxylation in the metabolic activation of tamoxifen in rat liver cells
Carcinogenesis, October 1, 1999; 20(10): 2003 - 2009.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
R. Davies, T. W. Gant, L. L. Smith, and J. A. Styles
Tamoxifen induces G:C->T:A mutations in the cII gene in the liver of lambda/lacI transgenic rats but not at 5'-CpG-3' dinucleotide sequences as found in the lacI transgene
Carcinogenesis, July 1, 1999; 20(7): 1351 - 1356.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
R. M. O'Regan and V. C. Jordan
RESPONSE: Re: Effects of the Antiestrogens Tamoxifen, Toremifene, and ICI 182,780 on Endometrial Cancer Growth
J Natl Cancer Inst, April 21, 1999; 91(8): 722a - 723a.
[Full Text] [PDF]

Home page
 CarcinogenesisHome page
P. L. Carmichael, S. Sardar, N. Crooks, P. Neven, I. Van Hoof, A. Ugwumadu, T. Bourne, E. Tomas, P. Hellberg, A. J. Hewer, et al.
Lack of evidence from HPLC 32P-post-labelling for tamoxifen–DNA adducts in the human endometrium
Carcinogenesis, February 1, 1999; 20(2): 339 - 342.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.